产品中心Cell Resources
联系我们CONTACT US
400-999-210024小时服务热线
产品概述
| 名称 | SK-OV-3 (人卵巢癌细胞) (STR鉴定正确) |
| 别称 | SKOV-3; SK.OV.3; SKOV3; Skov3; SKO3 |
| 背景描述 | SK-OV-3细胞是由G·Trempe和L·J·Old于1973年从卵巢肿瘤病人的腹水分离得到。SK-OV-3细胞对肿瘤坏死因子和几种细胞毒性药物包括白喉毒素、顺铂和阿霉素均耐受。SK-OV-3细胞在裸鼠中致瘤，且形成与卵巢原位癌一致的中度分化的腺癌。 |
| 种属 | 人 |
| 年龄（性别） | 女；64岁 |
| 组织来源 | 卵巢腺癌，腹水转移 |
| 生长特性 | 贴壁细胞 |
| 细胞形态 | 上皮细胞样 |
| 细胞类型 | 肿瘤细胞 |
| 肿瘤类型 | 卵巢癌细胞 |
| 生物安全等级 | 1 |
| 生长培养基 | McCoy's 5A＋10% FBS＋1% P/S |
| 推荐传代比例 | 1:2-1:4 |
| 推荐换液频率 | 2~3次/周 |
| 倍增时间 | ~20-48 hours |
| 冻存条件 | 冻存液：55% 基础培养基+40%FBS+5%DMSO 温度：液氮 |
| 培养条件 | 气相：空气，95%；CO2，5% 温度：37℃ |
| 致瘤性 | Yes, in nude mice; forms moderately well differentiated adenocarcinoma consistent with ovarian primary. |
| 抗原表达情况 | Blood Type B; Rh+ |
| 基因表达情况 | Blood Type B; Rh+ |
| 保藏机构 | ATCC; HTB-77 ECACC; 91091004 |
STR鉴定
-
STR位点信息
Amelogenin X CSF1PO 11 D2S1338 18,23 D3S1358 14 D5S818 11 D7S820 13 D8S1179 14,15 D13S317 8,11 D16S539 12 D18S51 16,17,18 D19S433 14,14.2 D21S11 30,31.2 FGA 24,25 PentaD 12,13 PentaE 5,13 TH01 9,9.3 TPOX 7,11 vWA 17,18 D6S1043 12 D12S391 22 D2S441 10,11.3 -
STR鉴定图
-
参考文献
-
A smart O2-generating nanocarrier optimizes drug transportation comprehensively for chemotherapy improving(2021/03/29)
作者：Xiaojuan Zhang, Chuanchuan He, Yun Sun
期刊：Acta Pharmaceutica Sinica B
DOI：10.1016/j.apsb.2021.04.021
影响因子 ：14.903
引用产品：CL-0215
-
Elevated expression of the rhythm gene NFIL3 promotes the progression of TNBC by activating NF-κB signaling through suppression of NFKBIA transcription(2022/02/18)
作者：Weiwei Yang , Jing Li, Minghui Zhang
期刊：Journal Of Experimental & Clinical Cancer Research
DOI：10.1186/s13046-022-02260-1
影响因子 ：12.658
引用产品：CL-0016 CL-0041 CL-0097 CL-0101 CL-0114 CL-0184 CL-0215 CL-0525
-
A solid lipid coated calcium peroxide nanocarrier enables combined cancer chemo/chemodynamic therapy with O2/H2O2 self-sufficiency(2021/1/6)
作者：Chuanchuan He, Xiaojuan Zhang, Chen Chen
期刊：Acta Biomaterialia
DOI：10.1016/j.actbio.2020.12.036
影响因子 ：10.6330
引用产品：CL-0215
-
Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization(2017/05/08)
作者：H Guo, Q Zhu, X Yu
期刊：Oncogene
影响因子 ：8.756
-
An Activity-Based Fluorogenic Probe Enables Cellular and in Vivo Profiling of Carboxylesterase Isozymes(2020/07/07)
作者：Shiyu Liu, Renyu Qu, Rongrong Li
期刊：Anal Chem
DOI：10.1021/acs.analchem.0c01554
影响因子 ：8.008
-
Knockdown of long non-coding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated EZH2 and SIRT1(2020/4/29)
作者：Yun Zhang, Hao Ai, Xue Fan
期刊：Biological Research
DOI：10.1186/s40659-020-00286-3
影响因子 ：7.6340
-
Isothiocyanate Iberin inhibits cell proliferation and induces cell apoptosis in the progression of ovarian cancer by mediating ROS accumulation and GPX1 expression(2021/06/17)
作者：Tingting Gong, Qian Guo, Xiao Li
期刊：Biomedicine & Pharmacotherapy
DOI：10.1016/j.biopha.2021.111533
影响因子 ：7.419
-
Oncogenic microRNA-181d binding to OGT contributes to resistance of ovarian cancer cells to cisplatin(2021/12/08)
作者：Wei Huang, Ling Chen, Kean Zhu
期刊：Cell Death Discovery
DOI：10.1038/s41420-021-00715-6
影响因子 ：7.1090
-
Combination of Chemotherapy and Photodynamic Therapy with Oxygen Self-Supply in the Form of Mutual Assistance for Cancer Therapy(2021/05/28)
作者：Ying Chen, Lei Zhang, Fangxuan Li
期刊：International Journal of Nanomedicine
影响因子 ：7.0330
引用产品：CL-0215
-
IR780-loaded folate-targeted nanoparticles for near-infrared fluorescence image-guided surgery and photothermal therapy in ovarian cancer(2019/04/18)
作者：Jiao Song, Ni Zhang, Liang Zhang
期刊：International Journal of Nanomedicine
影响因子 ：7.0330
引用产品：CL-0215
-
Knockdown of lncRNA ACTA2-AS1 reverses cisplatin resistance of ovarian cancer cells via inhibition of miR-378a-3p-regulated Wnt5a(2022/04/12)
作者：Chenxiao Lin, Meiyun Zheng, Youlin Yang
期刊：Bioengineered
DOI：10.1080/21655979.2022.2061181
影响因子 ：6.8320
-
CircSETDB1 knockdown inhibits the malignant progression of serous ovarian cancer through miR-129-3p-dependent regulation of MAP3K3(2021/11/17)
作者：Bo Li, Lu Zhang
期刊：Journal of Ovarian Research
DOI：10.1186/s13048-021-00875-0
影响因子 ：5.5060
-
Curcumin inhibits ovarian cancer progression by regulating circ-PLEKHM3/miR-320a/SMG1 axis(2021/11/16)
作者：Sifan Sun, Hailiang Fang
期刊：Journal of Ovarian Research
DOI：10.1186/s13048-021-00916-8
影响因子 ：5.5060
-
RNA-binding protein IGF2BP2 enhances circ_0000745 abundancy and promotes aggressiveness and stemness of ovarian cancer cells via the microRNA-3187-3p/ERBB4/PI3K/AKT axis(2021/11/13)
作者：Shengtan Wang, Zaihong Li , Genhai Zhu
期刊：Journal of Ovarian Research
DOI：10.1186/s13048-021-00917-7
影响因子 ：5.5060
-
The anticancer effect of extract of medicinal mushroom Sanghuangprous vaninii against human cervical cancer cell via endoplasmic reticulum stress-mitochondrial apoptotic pathway(2021/6/17)
作者：Pingya He, Yuhao Hou, Yue Yang
期刊：Journal Of Ethnopharmacology
影响因子 ：5.1950
-
CircLNPEP promotes the progression of ovarian cancer through regulating miR-876-3p/ WNT5A axis(2021/08/31)
作者：Wenwen Wang, Weiwei Zhang, Hongjun Guo
期刊：Cell Cycle
DOI：10.1080/15384101.2021.1965723
影响因子 ：5.173
-
Long non-coding RNA SNHG25 promotes epithelial ovarian cancer progression by up-regulating COMP(2021/1/16)
作者：Yinglei Liu, Boqun Xu, Manhua Liu
期刊：Journal of Cancer
影响因子 ：4.2070
引用产品：CL-0215
-
LPA3 is a precise therapeutic target and potential biomarker for ovarian cancer(2022/01/04)
作者：Pengfei Zhao, Qingru Yun, Aodungerile Li
期刊：Medical Oncology
DOI：10.1007/s12032-021-01616-5
影响因子 ：3.7380
-
miR‑576‑3p overexpression enhances cisplatin sensitivity of ovarian cancer cells by dysregulating PD‑L1 and cyclin D1(2020/11/23)
作者：Ying Zuo, Wei Zheng, Qing Tang
期刊：Molecular Medicine Reports
影响因子 ：3.4230
引用产品：CL-0215
-
Screening of CXC chemokines in the microenvironment of ovarian cancer and the biological function of CXCL10(2021/11/18)
作者：Weiyuan Li, Ji-ao Ma, Xun Sheng
期刊：World Journal of Surgical Oncology
DOI：10.1186/s12957-021-02440-x
影响因子 ：3.2530
-
The Antitumor Potential of Extract of the Oak Bracket Medicinal Mushroom Inonotus baumii in SMMC-7721 Tumor Cells(2019/09/22)
作者：Yue Yang, Pingya He
期刊：Evidence-Based Complementary and Alternative Medicine
影响因子 ：2.650
